Investor List:

Top Therapeutics Series A Investors in Boston / New England (29)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Therapeutics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Manufacturing (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Manufacturing (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series A), Investors in Digital Health (Series A), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Manufacturing (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Manufacturing (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Los Angeles / Southern California (Other Lists), Investors in Boston / New England (Other Lists), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists)
Photo of Wasim Malik, Managing Partner at Iaso Ventures
Wasim Malik
Iaso Ventures·Managing Partner
Sweet spot: $500K
Range: $100K - $2.0M
Investors in Boston (MA)
Investors in Therapeutics (Pre-seed), Investors in Impact (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in BioTech (Pre-seed), Investors in AI (Pre-seed), Investors in Health IT (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Impact (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health IT (Pre-seed), Investors in AI (Pre-seed), Investors in Therapeutics (Seed), Investors in Impact (Seed), Investors in DeepTech (Seed), Investors in Therapeutics (Seed), Investors in Pharmaceuticals (Seed), Investors in Digital Health (Seed), Investors in AI (Seed), Investors in Health IT (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in DeepTech (Seed), Investors in Impact (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in AI (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Impact (Series A), Investors in DeepTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Digital Health (Series A), Investors in Health IT (Series A), Investors in AI (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Impact (Series A), Investors in DeepTech (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in AI (Series A), Investors in Diverse Investors (Other Lists), Investors in Boston / New England (Other Lists), Investors in Investors who were founders (Other Lists)
Photo of Jorge Cortell, General Partner at Unveil Pharma
Jorge Cortell
Unveil Pharma·General Partner
Sweet spot: $1.5M
Range: $500K - $20.0M
Investors in Cambridge (MA), Investors in Boston (MA), Investors in Singapore
Investors in Therapeutics (Pre-seed), Investors in Drug Delivery (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Drug Delivery (Pre-seed), Investors in Diagnostics (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health IT (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Health & Hospital Services (Pre-seed), Investors in BioTech (Pre-seed), Investors in Health IT (Pre-seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Drug Delivery (Seed), Investors in Medical Devices (Seed), Investors in Therapeutics (Seed), Investors in Drug Delivery (Seed), Investors in Pharmaceuticals (Seed), Investors in Diagnostics (Seed), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Medical Devices (Series A), Investors in Drug Delivery (Series A), Investors in Therapeutics (Series A), Investors in Pharmaceuticals (Series A), Investors in Diagnostics (Series A), Investors in Drug Delivery (Series A), Investors in Digital Health (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Boston / New England (Other Lists), Investors in Diverse Investors (Other Lists), Investors in Investors who were founders (Other Lists), Investors in Investors who invested in female founders (Other Lists), Investors in Investors who invested in diverse founders (Other Lists)
Photo of Wes Schifone, Scout at CRV
Wes Schifone
CRV·Scout
Sweet spot: $50K
Range: $25K - $100K
Investors in Boston (MA)
Investors in Therapeutics (Seed), Investors in Wellness & Fitness (Seed), Investors in Therapeutics (Seed), Investors in Web3/Blockchain (Seed), Investors in Consumer Health (Seed), Investors in Digital Health (Seed), Investors in Wellness & Fitness (Seed), Investors in Health & Hospital Services (Seed), Investors in Health IT (Seed), Investors in Web3/Crypto (Seed), Investors in Consumer Health (Seed), Investors in Digital Health (Seed), Investors in Web3/Blockchain (Seed), Investors in Health & Hospital Services (Seed), Investors in Web3/Crypto (Seed), Investors in Health IT (Seed), Investors in Therapeutics (Series A), Investors in Wellness & Fitness (Series A), Investors in Therapeutics (Series A), Investors in Web3/Blockchain (Series A), Investors in Consumer Health (Series A), Investors in Digital Health (Series A), Investors in Health & Hospital Services (Series A), Investors in Wellness & Fitness (Series A), Investors in Health IT (Series A), Investors in Web3/Crypto (Series A), Investors in Consumer Health (Series A), Investors in Digital Health (Series A), Investors in Web3/Blockchain (Series A), Investors in Web3/Crypto (Series A), Investors in Health & Hospital Services (Series A), Investors in Health IT (Series A), Investors in Therapeutics (Series B), Investors in Wellness & Fitness (Series B), Investors in Therapeutics (Series B), Investors in Web3/Blockchain (Series B), Investors in Consumer Health (Series B), Investors in Wellness & Fitness (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Health & Hospital Services (Series B), Investors in Consumer Health (Series B), Investors in Web3/Crypto (Series B), Investors in Web3/Blockchain (Series B), Investors in Digital Health (Series B), Investors in Health & Hospital Services (Series B), Investors in Health IT (Series B), Investors in Web3/Crypto (Series B), Investors in Boston / New England (Other Lists), Investors in Angel, Scout, and Solo-Capitalists (Other Lists)
Photo of Lou Tartaglia, Managing Partner at Cure Ventures
Lou Tartaglia
Cure Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boston (MA)
Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Boston / New England (Other Lists)
Photo of Cavin Mozarmi, Senior Associate at REMUS Capital
Cavin Mozarmi
REMUS Capital·Senior Associate
Sweet spot: $15.0M
Range: $10.0M - $20.0M
Investors in Boston (MA)
Investors in Therapeutics (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Enterprise (Pre-seed), Investors in FinTech (Pre-seed), Investors in SaaS (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Enterprise (Pre-seed), Investors in SaaS (Pre-seed), Investors in FinTech (Pre-seed), Investors in Therapeutics (Seed), Investors in DeepTech (Seed), Investors in Therapeutics (Seed), Investors in SaaS (Seed), Investors in Enterprise (Seed), Investors in FinTech (Seed), Investors in DeepTech (Seed), Investors in SaaS (Seed), Investors in Enterprise (Seed), Investors in FinTech (Seed), Investors in Therapeutics (Series A), Investors in DeepTech (Series A), Investors in Therapeutics (Series A), Investors in SaaS (Series A), Investors in Enterprise (Series A), Investors in FinTech (Series A), Investors in DeepTech (Series A), Investors in SaaS (Series A), Investors in Enterprise (Series A), Investors in FinTech (Series A), Investors in Therapeutics (Series B), Investors in DeepTech (Series B), Investors in Therapeutics (Series B), Investors in SaaS (Series B), Investors in Enterprise (Series B), Investors in DeepTech (Series B), Investors in FinTech (Series B), Investors in SaaS (Series B), Investors in Enterprise (Series B), Investors in FinTech (Series B), Investors in Boston / New England (Other Lists)
Photo of Aaron Nelson, Managing Director at Novartis Venture Fund
Aaron Nelson
Novartis Venture Fund·Managing Director
Sweet spot: $7.5M
Range: $5.0M - $10.0M
Investors in Cambridge (MA)
Investors in Chemicals (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Chemicals (Seed), Investors in Chemicals (Series A), Investors in Therapeutics (Series A), Investors in Chemicals (Series A), Investors in BioTech (Series A), Investors in Therapeutics (Series A), Investors in BioTech (Series A), Investors in Boston / New England (Other Lists)
Photo of Soyoung Park, General Partner at 1004 Venture Partners
Soyoung Park
1004 Venture Partners·General Partner
Sweet spot: $500K
Range: $100K - $10.0M
Investors in Asia, Investors in Boston / New England, Investors in SF Bay Area (CA), Investors in Europe, Investors in United Kingdom, Investors in United States
Investors in Wellness & Fitness (Seed), Investors in Diagnostics (Seed), Investors in Therapeutics (Seed), Investors in Generative Tech/AI (Seed), Investors in Wellness & Fitness (Seed), Investors in Therapeutics (Seed), Investors in Robotics (Seed), Investors in Medical Devices (Seed), Investors in Consumer Health (Seed), Investors in Therapeutics (Seed), Investors in Generative Tech/AI (Seed), Investors in Digital Health (Seed), Investors in Diagnostics (Seed), Investors in Health IT (Seed), Investors in BioTech (Seed), Investors in Generative Tech/AI (Seed), Investors in Consumer Health (Seed), Investors in Wellness & Fitness (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Medical Devices (Seed), Investors in Health IT (Seed), Investors in Robotics (Seed), Investors in Digital Health (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Diagnostics (Seed), Investors in Medical Devices (Seed), Investors in Robotics (Seed), Investors in Consumer Health (Seed), Investors in Wellness & Fitness (Series A), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Generative Tech/AI (Series A), Investors in Therapeutics (Series A), Investors in Diagnostics (Series A), Investors in Robotics (Series A), Investors in Medical Devices (Series A), Investors in Wellness & Fitness (Series A), Investors in Consumer Health (Series A), Investors in Generative Tech/AI (Series A), Investors in Medical Devices (Series A), Investors in Digital Health (Series A), Investors in Diagnostics (Series A), Investors in Health IT (Series A), Investors in BioTech (Series A), Investors in Robotics (Series A), Investors in Wellness & Fitness (Series A), Investors in Generative Tech/AI (Series A), Investors in Consumer Health (Series A), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in Health IT (Series A), Investors in Digital Health (Series A), Investors in Consumer Health (Series A), Investors in Health IT (Series A), Investors in Therapeutics (Series A), Investors in Digital Health (Series A), Investors in BioTech (Series A), Investors in Robotics (Series A), Investors in Therapeutics (Series B), Investors in Wellness & Fitness (Series B), Investors in Therapeutics (Series B), Investors in Wellness & Fitness (Series B), Investors in Generative Tech/AI (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series B), Investors in Therapeutics (Series B), Investors in Robotics (Series B), Investors in Medical Devices (Series B), Investors in Diagnostics (Series B), Investors in Consumer Health (Series B), Investors in Medical Devices (Series B), Investors in Generative Tech/AI (Series B), Investors in Digital Health (Series B), Investors in Wellness & Fitness (Series B), Investors in BioTech (Series B), Investors in Robotics (Series B), Investors in Health IT (Series B), Investors in Generative Tech/AI (Series B), Investors in Consumer Health (Series B), Investors in Medical Devices (Series B), Investors in Digital Health (Series B), Investors in Health IT (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Digital Health (Series B), Investors in Consumer Health (Series B), Investors in Robotics (Series B), Investors in BioTech (Series B), Investors in Boston / New England (Other Lists), Investors in San Francisco Bay Area (Other Lists), Investors in Diverse Investors (Other Lists), Investors in Investors who invested in diverse founders (Other Lists), Investors in Female Investors (Other Lists)